Cortisol is a hormone produced mainly by the cortex of the adrenal glands, the paired organs situated above the kidneys. It is the principal naturally occurring glucocorticoid in humans: a steroid that helps coordinate fuel availability, cardiovascular function, immune activity, and adaptation to changing demands. Cortisol is essential to normal homeostasis, not merely a substance released during psychological stress. Its secretion follows daily and shorter pulsatile rhythms, and its effects depend on concentration, timing, tissue sensitivity, and local metabolism.
Cortisol and hydrocortisone are the same chemical substance; hydrocortisone is the name generally used for the pharmaceutical preparation. Cortisol belongs to the broader corticosteroid family, which also includes mineralocorticoids such as aldosterone and many synthetic medicines. Persistent excess causes Cushing syndrome, whereas inadequate production or impaired stimulation of the adrenal cortex causes adrenal insufficiency. Understanding cortisol therefore connects steroid chemistry, biological timing, stress physiology, laboratory testing, and the therapeutic use of glucocorticoids.
Chemical identity and adrenal synthesis
Cortisol is a steroid with the molecular formula and a molar mass of approximately . Its structure contains the four fused rings characteristic of steroids, with hydroxyl groups at carbon positions 11, 17, and 21 and ketone groups at positions 3 and 20. Small structural differences distinguish it from related hormones and strongly affect biological activity. Cortisone, for example, has a ketone rather than a hydroxyl group at position 11 and has much less direct activity at the glucocorticoid receptor. Corticosterone lacks cortisol’s 17-hydroxyl group and is the principal circulating glucocorticoid in many rodents, rather than in humans.
Most circulating cortisol originates in the zona fasciculata, the middle layer of the adrenal cortex. Like other steroid hormones, it is synthesized from cholesterol. Adrenal cells obtain cholesterol from circulating lipoproteins and from intracellular stores, and can also synthesize it. An important regulated step is the movement of cholesterol into mitochondria by the steroidogenic acute regulatory protein, usually abbreviated StAR. Within mitochondria, the enzyme CYP11A1 cleaves cholesterol’s side chain to form pregnenolone. Subsequent reactions occur across the mitochondria and smooth endoplasmic reticulum.
The main biosynthetic route proceeds through 17-hydroxylated intermediates. CYP17A1 supplies 17α-hydroxylase activity; 3β-hydroxysteroid dehydrogenase participates in the formation of 17-hydroxyprogesterone; CYP21A2 converts that compound to 11-deoxycortisol; and mitochondrial CYP11B1 performs the final 11β-hydroxylation to cortisol. These reactions require electron-transfer systems and metabolic cofactors. Unlike peptide hormones, cortisol is not stored in large secretory granules. Production is closely coupled to release, and the newly synthesized steroid passes out of the adrenal cell into the circulation.
Defects in these enzymes illustrate the connections between cortisol synthesis and other adrenal pathways. In congenital adrenal hyperplasia caused by 21-hydroxylase deficiency, reduced cortisol production removes part of the normal restraint on pituitary stimulation. Precursors accumulate and are diverted toward androgen production; severe forms also impair aldosterone synthesis. In 11β-hydroxylase deficiency, the accumulation of precursors with mineralocorticoid activity can instead produce high blood pressure. Thus a block in cortisol synthesis can alter several hormone systems rather than producing an isolated cortisol abnormality. Outside the adrenal glands, some tissues can generate active cortisol locally, especially by converting cortisone, but this generally serves tissue-specific regulation rather than replacing adrenal endocrine secretion.
Hypothalamic–pituitary control and biological timing
Cortisol secretion is governed principally by the hypothalamic–pituitary–adrenal axis, commonly abbreviated HPA axis. Neurons in the hypothalamus, particularly the paraventricular nucleus, release corticotropin-releasing hormone into the portal circulation connecting the hypothalamus to the anterior pituitary. Arginine vasopressin can amplify its effects. Pituitary corticotroph cells then release adrenocorticotropic hormone, or ACTH, derived from the precursor proopiomelanocortin. ACTH binds the melanocortin 2 receptor on adrenal cortical cells and activates signaling through cyclic AMP and protein kinase A. This rapidly promotes cholesterol delivery for steroid synthesis and, over longer periods, supports the growth and steroid-producing capacity of the adrenal cortex.
Cortisol restrains this system through negative feedback at the pituitary, hypothalamus, and connected brain networks. Feedback operates over several timescales: some effects develop rapidly, whereas others depend on altered gene transcription and protein production. The axis is consequently a dynamic feedback system rather than a simple switch that turns on during stress and off afterward. Prolonged exposure to glucocorticoid medicines suppresses endogenous ACTH secretion. If suppression is substantial and sustained, the adrenal cortex loses some of its capacity to produce cortisol independently, a mechanism central to glucocorticoid-induced adrenal insufficiency.
A strong circadian rhythm organizes secretion across approximately 24 hours. In people with a conventional nighttime sleep schedule, cortisol usually rises during the latter part of sleep, reaches high concentrations around the transition to waking, and declines toward a low point near habitual bedtime. The suprachiasmatic nucleus, which receives information about environmental light, helps coordinate this timing through neural and endocrine pathways. Sleep, feeding, activity, and work schedules modify the observed pattern. Cortisol also displays ultradian pulses, often separated by roughly one to two hours, superimposed on the daily rhythm. These pulses influence receptor activation and gene regulation, so equivalent average concentrations do not necessarily imply equivalent biological exposure.
The cortisol awakening response is a further phenomenon: concentrations commonly increase during the first 30–45 minutes after awakening. It is related to, but not identical with, the underlying circadian rise. Its measured size depends strongly on sample timing, adherence to collection procedures, and the circumstances of awakening. Acute infection, injury, hypoglycemia, and other substantial challenges can increase HPA-axis activity beyond the usual daily pattern. Psychological stress can also activate the axis, but responses vary with novelty, controllability, social evaluation, previous experience, and individual physiology. A single high or low measurement therefore cannot establish how much chronic stress a person has experienced.
Transport, receptors, and local metabolism
Once released, most cortisol circulates bound to proteins, especially corticosteroid-binding globulin, also called transcortin, and, more weakly, albumin. Under ordinary conditions only a small proportion is unbound. The free fraction is more readily available to enter cells, while protein binding acts as a circulating reservoir and influences distribution and clearance. Binding is not fixed: corticosteroid-binding globulin can become relatively saturated at high concentrations, and its concentration changes with physiological and disease states. Estrogen exposure and pregnancy commonly increase binding globulin and total serum cortisol. Severe illness, reduced liver protein synthesis, or protein loss can lower measured total cortisol without a proportionate reduction in the free fraction.
Many cortisol effects are mediated by the glucocorticoid receptor, encoded by the gene NR3C1. In the absence of hormone, this receptor participates in a complex with chaperone proteins. Cortisol binding changes the receptor complex and facilitates its interaction with the nucleus, where it regulates gene expression. Receptor complexes can bind glucocorticoid response elements in DNA, interact with other transcription factors, and recruit proteins that modify chromatin or transcriptional activity. The resulting changes can increase or decrease gene expression. Although anti-inflammatory actions are sometimes described simply as transcriptional repression, both gene activation and repression contribute to the physiological and therapeutic response.
Cortisol also binds the mineralocorticoid receptor, which has high affinity for both cortisol and aldosterone. Because circulating cortisol is much more abundant than aldosterone, selective aldosterone signaling requires additional protection in tissues such as the distal nephron. The enzyme 11β-hydroxysteroid dehydrogenase type 2, or 11β-HSD2, converts cortisol to cortisone, thereby reducing cortisol access to mineralocorticoid receptors. In contrast, 11β-HSD1 acts mainly as a reductase in intact cells, regenerating cortisol from cortisone in tissues including liver and adipose tissue. These enzymes allow intracellular exposure to differ from what a blood concentration alone would predict. Inhibition of 11β-HSD2 by compounds derived from licorice can permit excessive renal mineralocorticoid receptor activation.
The liver converts cortisol into reduced and conjugated metabolites, which are subsequently excreted largely through the kidneys. Only a small fraction of cortisol production appears in urine as unchanged free cortisol. Circulating cortisol has a plasma half-life of roughly an hour to an hour and a half, although this varies with binding and physiological state. Its biological effects can persist longer because altered proteins and cellular programs outlast the hormone itself. Rapid effects that are not readily explained by new gene transcription also occur, including changes in signaling and membrane-associated processes; these complement, rather than replace, the receptor’s well-established genomic actions.
Metabolic, cardiovascular, and skeletal functions
Cortisol helps preserve circulating fuel during fasting and increased physiological demand. In the liver, it promotes the expression of enzymes involved in gluconeogenesis, the production of glucose from substrates such as amino acids and glycerol. It also supports hepatic glycogen storage, creating a reserve that can be mobilized by other signals. In muscle and adipose tissue, sustained glucocorticoid exposure can reduce insulin-mediated glucose uptake. These actions oppose some effects of insulin, but normal cortisol physiology is not simply equivalent to insulin antagonism: it coordinates fuel production, storage, and mobilization across different tissues and times of day.
Protein and fat metabolism supply substrates for this coordination. Cortisol can promote protein breakdown in skeletal muscle, making amino acids available for hepatic metabolism. It also influences fat breakdown and the responsiveness of adipose tissue to catecholamines. With chronic excess, however, fat accumulation in central and certain other depots can coexist with loss of muscle and thinning of the limbs. The distribution reflects differences among fat depots, interactions with insulin and appetite, and local glucocorticoid metabolism. Persistent excess therefore favors insulin resistance, hyperglycemia, and sometimes diabetes mellitus, while physiological secretion helps maintain glucose availability during fasting.
Cortisol also has important permissive effects on the cardiovascular system. It maintains vascular responsiveness to vasoconstrictors such as norepinephrine and supports normal circulatory function. Deficiency can contribute to low blood pressure, especially during illness. At excessive concentrations, cortisol promotes hypertension through several mechanisms, including altered vascular reactivity, effects on renal sodium handling, and activation of mineralocorticoid receptors when protective cortisol inactivation is overwhelmed. Cortisol also affects water balance partly by restraining vasopressin secretion. In deficiency, increased vasopressin can impair free-water excretion and produce hyponatremia even when aldosterone production remains intact.
Bone and connective tissue are especially sensitive to prolonged glucocorticoid excess. Cortisol reduces osteoblast activity and bone formation; effects on bone resorption vary with the stage and duration of exposure. Reduced intestinal calcium absorption, altered reproductive hormone function, muscle weakness, and increased fall risk can further compromise skeletal strength. These mechanisms contribute to osteoporosis and fractures in Cushing syndrome and during sustained pharmacological treatment. In skin, reduced collagen synthesis and impaired tissue maintenance contribute to easy bruising, thin skin, and delayed wound repair. In children, excessive glucocorticoid exposure suppresses linear growth through effects on growth-related signaling, cartilage, and bone formation. These consequences arise from sustained exposure and are distinct from the adaptive functions of normal daily cortisol secretion.
Immune regulation, brain function, and development
Cortisol regulates the immune system at multiple levels. It alters leukocyte trafficking, the production of signaling molecules, and the activity of cells that initiate and sustain inflammation. Glucocorticoid receptor signaling can inhibit transcriptional programs involving NF-κB and AP-1 while inducing anti-inflammatory proteins such as annexin A1 and glucocorticoid-induced leucine zipper. The consequences depend on cell type, concentration, and timing. Physiological glucocorticoid signaling helps constrain excessive immune activation, whereas pharmacological exposure can produce much stronger anti-inflammatory effects and immunosuppression.
Blood-cell counts illustrate why circulating measurements do not always directly represent immune capability. Glucocorticoids commonly increase the number of neutrophils measured in blood, partly through demargination and altered movement out of the circulation. At the same time, circulating lymphocyte and eosinophil counts often decrease through redistribution and other mechanisms. A raised neutrophil count during glucocorticoid treatment therefore need not indicate an increased production of effective antimicrobial defenses. Sustained excess can impair responses to infection, and suppression of inflammatory signs may alter how infection presents clinically. Endogenous cortisol release during infection is nevertheless part of a coordinated response involving immune signals, autonomic activity, and metabolism.
In the brain, mineralocorticoid and glucocorticoid receptors participate in the regulation of arousal, appraisal, learning, memory, and emotional responses. The hippocampus, amygdala, and prefrontal networks are among the regions involved. High-affinity mineralocorticoid receptors are substantially occupied at lower cortisol concentrations, whereas glucocorticoid receptor activation becomes more prominent near daily peaks and during stress. Cortisol can enhance consolidation of some emotionally salient memories while impairing retrieval or working-memory performance under other conditions. The outcome depends on timing relative to learning, the accompanying catecholamine response, and the task being studied.
Associations between altered cortisol patterns and depression, post-traumatic stress disorder, or sleep disturbance do not define a uniform endocrine abnormality. Findings differ across patient groups, disease stages, medications, and measurement methods. Neither a single cortisol concentration nor a daily profile is a stand-alone diagnostic test for these psychiatric conditions.
During fetal development, glucocorticoids contribute to the maturation of organs, including the lungs. Placental 11β-HSD2 converts much maternal cortisol to cortisone, limiting fetal exposure without forming an absolute barrier. Maternal cortisol concentrations, placental metabolism, fetal adrenal activity, and gestational age all influence exposure. Synthetic antenatal glucocorticoids used in selected obstetric circumstances have pharmacological properties distinct from maternal cortisol, including different susceptibility to placental metabolism. Experimental and observational research links altered prenatal glucocorticoid exposure with later physiological outcomes, but the pathways involve many interacting maternal, placental, and fetal factors.
Measurement and interpretation
Cortisol can be measured in blood, saliva, urine, and hair, but these specimens answer different questions. A serum measurement generally reports total cortisol unless a specific free-cortisol method is used. Salivary cortisol more closely reflects the unbound fraction, while a complete 24-hour urine collection estimates integrated excretion of urinary free cortisol over that interval. Hair analysis attempts to characterize exposure across longer periods, but hair growth, cosmetic treatment, external contamination, and laboratory methods complicate interpretation. Results from different specimen types are therefore not interchangeable measurements of a single fixed quantity.
Timing is fundamental. A morning serum sample may help assess suspected adrenal insufficiency because concentrations are normally relatively high then, whereas late-night salivary sampling can detect loss of the normal nocturnal nadir in suspected Cushing syndrome. Reference intervals and decision thresholds depend on the assay, specimen, sampling protocol, and clinical question. For unit conversion, of cortisol is approximately . Quoting a numerical result without its units and collection time can therefore be misleading. Normal circadian changes and short pulses also mean that apparently discordant samples need not represent laboratory error.
Immunoassays are widely used because they are automated and practical, but some cross-react with related steroids or synthetic glucocorticoids. Liquid chromatography coupled with tandem mass spectrometry can distinguish compounds more specifically, although analytical performance still depends on calibration, sample preparation, and validated procedures. More specific assays often produce lower results than older immunoassays in certain testing contexts. Historical diagnostic cutoffs therefore cannot always be transferred unchanged to modern methods. Measurement of free serum cortisol is technically more demanding and has less widely standardized clinical interpretation than routine total-cortisol testing.
Dynamic tests examine the behavior of the regulatory system rather than a single resting concentration. In the ACTH stimulation test, synthetic ACTH is administered and the cortisol response is measured. This assesses adrenal responsiveness, although recently developed central adrenal insufficiency can sometimes retain a response before the cortex has lost substantial capacity. Dexamethasone suppression testing evaluates whether an administered glucocorticoid appropriately suppresses endogenous cortisol production. Insulin-induced hypoglycemia can test the integrated axis in selected specialist settings, but entails risks and is not a routine substitute for simpler tests. Protocol and assay-specific interpretation are essential to all these procedures.
Binding-protein changes, kidney dysfunction, incomplete urine collection, altered sleep schedules, acute illness, and interacting medicines can affect interpretation. Oral estrogen can increase total serum cortisol by increasing binding globulin; low albumin and binding globulin in critical illness can have the opposite effect. Medicines that alter dexamethasone metabolism can distort suppression-test results. Alcohol-related illness, severe depression, and other states can produce non-neoplastic hypercortisolism that overlaps biochemically with Cushing syndrome. Cortisol is consequently a context-dependent biomarker, not a direct numerical scale of health, resilience, or everyday psychological stress.
Cortisol excess and Cushing syndrome
Cushing syndrome denotes the clinical consequences of prolonged excessive glucocorticoid exposure. The most common overall cause is treatment with glucocorticoid medicines, which can produce the syndrome while suppressing the body’s own cortisol secretion. Endogenous Cushing syndrome is less common and results from excessive internal production. It is divided into ACTH-dependent forms, in which ACTH drives adrenal secretion, and ACTH-independent forms, in which the adrenal cortex produces cortisol without normal pituitary control. The distinction is important because similar physical manifestations can arise from very different underlying sources.
Cushing disease specifically refers to an ACTH-secreting pituitary tumor; it is not a synonym for every form of Cushing syndrome. Other ACTH-dependent cases arise from ectopic hormone secretion, often by neuroendocrine tumors outside the pituitary. ACTH-independent causes include cortisol-producing adrenal adenomas, adrenocortical carcinoma, and some forms of bilateral adrenal nodular disease. Sustained autonomous cortisol secretion usually suppresses normal pituitary ACTH through feedback, whereas ACTH-dependent disease maintains inappropriate stimulation despite elevated cortisol. Some adrenal lesions produce subtler biochemical excess without the characteristic appearance of overt Cushing syndrome; this is often termed mild autonomous cortisol secretion.
Clinical manifestations include central weight gain, facial rounding, muscle weakness, easy bruising, broad reddish-purple stretch marks, hypertension, and disturbances of glucose regulation. Proximal muscle weakness, unexplained bruising, and characteristic striae can be more discriminating than common findings such as weight gain alone. Bone loss, fractures, menstrual disturbance, reduced gonadal function, sleep changes, and cognitive or mood symptoms also occur. Children may show weight gain accompanied by reduced height velocity. Infection, cardiovascular complications, and increased thrombosis risk contribute substantially to the disease burden.
Establishing endogenous hypercortisolism generally requires validated biochemical testing that accounts for physiological confounders and medication exposure. Common tests assess late-night salivary cortisol, urinary free cortisol, or suppression after dexamethasone. Once excess is established, ACTH measurement helps separate ACTH-dependent from ACTH-independent disease. Imaging and, in selected cases, specialized venous sampling then help locate the source. Imaging alone cannot establish that an incidental pituitary or adrenal lesion is responsible for cortisol excess.
Treatment is directed at the cause and may include tumor removal, medicines that inhibit steroid synthesis, pituitary-directed drugs, or glucocorticoid receptor antagonism. Surgery that successfully removes an autonomous source can leave temporary or persistent adrenal insufficiency because normal tissues have been suppressed. Recovery of the HPA axis can be prolonged, and the restoration of biochemical control does not necessarily coincide with immediate recovery of muscle, bone, cardiovascular, or cognitive function.
Cortisol deficiency and therapeutic hydrocortisone
Adrenal insufficiency occurs when cortisol production is inadequate for the body’s requirements. In primary adrenal insufficiency, the adrenal cortex itself is damaged or dysfunctional. Autoimmune adrenalitis is a major cause in many settings; other causes include infections, hemorrhage, infiltrative disease, genetic disorders, and bilateral adrenal removal. The term Addison disease generally refers to primary adrenal insufficiency. Because adrenal damage may also impair aldosterone production, primary disease can involve salt loss, volume depletion, hyperkalemia, and increased renin as well as cortisol deficiency.
Central adrenal insufficiency results from inadequate hypothalamic or pituitary stimulation. Pituitary tumors, surgery, radiation, and other disorders can reduce ACTH secretion. Prolonged glucocorticoid treatment is another important cause of HPA-axis suppression. Aldosterone is usually relatively preserved in central disease because its regulation depends mainly on potassium and the renin–angiotensin system. Hyperkalemia is therefore less characteristic than in primary adrenal failure, although hyponatremia can occur through increased vasopressin and impaired water excretion. In primary disease, increased ACTH and related peptides can produce skin hyperpigmentation; this mechanism is absent when ACTH secretion is deficient.
Symptoms can include fatigue, muscle weakness, loss of appetite, weight loss, nausea, abdominal discomfort, and postural hypotension. These are nonspecific and overlap with many other conditions. Severe deficiency can culminate in an adrenal crisis, with hypotension or shock, vomiting, abdominal symptoms, electrolyte disturbances, and sometimes hypoglycemia. Infection, injury, or interruption of glucocorticoid replacement may precipitate a crisis because the normal increase in cortisol availability cannot occur. Crisis management uses parenteral glucocorticoids and fluid resuscitation, alongside treatment of the precipitating cause. It is an acute endocrine emergency rather than simply an unusually low laboratory value.
Hydrocortisone replaces the missing hormone in adrenal insufficiency. Conventional oral preparations are absorbed relatively quickly and have a shorter duration of action than many synthetic glucocorticoids. Replacement regimens therefore commonly divide administration across the day, with greater exposure earlier rather than late at night. Modified-release preparations and pump-based delivery have been developed to reproduce aspects of physiological timing more closely. No conventional regimen perfectly recreates the combined circadian and ultradian secretion of a healthy adrenal axis. Primary adrenal insufficiency may also require replacement of mineralocorticoid activity, which is a separate physiological requirement.
Hydrocortisone is also used pharmacologically for anti-inflammatory and immunomodulatory effects. Topical preparations treat several inflammatory skin disorders, and systemic preparations have uses in selected severe inflammatory and critical illnesses. Synthetic agents such as prednisone and dexamethasone differ in glucocorticoid potency, mineralocorticoid activity, metabolism, and duration. Pharmaceutical glucocorticoids are therefore not interchangeable on a milligram-for-milligram basis. Their adverse effects depend on systemic exposure, treatment duration, route, and susceptibility. Prolonged use can both produce features of glucocorticoid excess and suppress endogenous cortisol production, explaining why pharmacological excess and physiological deficiency can coexist in the same person.
Discovery and continuing research
The clinical importance of the adrenal glands became clear before cortisol itself was isolated. In 1855, Thomas Addison described a syndrome associated with disease of the adrenal capsules, linking characteristic weakness, pigmentation, and systemic deterioration to adrenal pathology. Subsequent experiments established that the adrenal glands were necessary for survival, while improved anatomical and physiological methods distinguished the functions of cortex and medulla. The later discovery of epinephrine explained important medullary actions but did not account for the life-sustaining functions of the cortex, directing attention toward cortical substances.
During the 1930s, Edward C. Kendall and Tadeus Reichstein independently contributed to the isolation and chemical characterization of adrenal cortical steroids. Different compounds were initially designated by letters before their structures and biological relationships were clarified. Cortisol became known as compound F in Kendall’s nomenclature, whereas compound E was cortisone. The distinction remained important: cortisol is an active glucocorticoid, while cortisone can be converted to cortisol within tissues. Advances in steroid chemistry made it possible to connect particular molecular structures with effects on carbohydrate metabolism, electrolyte balance, and inflammation.
The dramatic clinical demonstration of cortisone’s effects in rheumatoid arthritis by Philip S. Hench and colleagues in 1948 helped establish corticosteroid therapy. Kendall, Reichstein, and Hench shared the 1950 Nobel Prize in Physiology or Medicine for discoveries concerning adrenal cortical hormones, their structure, and biological effects. Subsequent experience revealed both the therapeutic power of glucocorticoids and the complications of sustained exposure. The development of synthetic agents allowed changes in anti-inflammatory potency, sodium-retaining activity, and duration, while endocrine testing clarified the suppression and recovery of normal adrenal function.
Later research shifted from the identification of circulating hormones to receptors, intracellular metabolism, and time-dependent signaling. The discovery and characterization of glucocorticoid receptors helped explain how one hormone could influence many tissues while producing different responses in each. Molecular studies of 11β-HSD enzymes established that local hormone activation and inactivation are major determinants of tissue exposure. Research on pulsatile secretion showed that delivery patterns can change receptor dynamics and transcription even when average hormone concentrations appear similar.
Current research includes more physiological replacement methods, tissue-selective modulation of glucocorticoid action, improved interpretation of cortisol in critical illness, and the development of minimally invasive monitoring technologies. Human studies of stress-related cortisol patterns increasingly emphasize repeated sampling, careful timing, and the distinction between association and causation. Wearable sweat sensors and other emerging approaches face challenges involving very low concentrations, specimen contamination, calibration, and uncertain relationships to circulating free cortisol. Translating such measurements into clinical information requires validation against specific physiological or diagnostic questions rather than simply demonstrating that cortisol can be detected.